← Back
Data updated: Mar 29, 2026
SHIONOGI INC
Infectious DiseaseGastroenterologyMetabolic
Specialty
SHIONOGI INC is a specialty pharmaceutical company focused on Infectious Disease, Gastroenterology, Metabolic. Key products include FETROJA.
1993
Since
8
Drugs
-
Trials
1
Approved (2yr)
Top Drug Revenues Pro
Loading...
Revenue Over Time Pro
Loading...
Therapeutic Areas
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Infectious Disease 74%
1 drugs Phase 3: 3 Phase 2: 5 Phase 1: 1
Gastroenterology 10%
0 drugs Phase 2: 1 Phase 1: 2
Metabolic 10%
0 drugs Phase 2: 1 Phase 1: 2
Oncology 5%
0 drugs Phase 1: 2
Pipeline Forecast
Loading...
Loading...
Upcoming Trial Milestones Pro
Loading...
Patent Cliff Pro
Loading...
Loading...
Loading...
Competitors by Therapeutic Area
Pfizer big-pharma
Oncology, Infectious Disease, Gastroenterology
Merck big-pharma
Oncology, Infectious Disease, Metabolic
Johnson & Johnson big-pharma
Oncology, Infectious Disease, Metabolic
Sanofi big-pharma
Metabolic, Oncology, Infectious Disease
Bristol-Myers Squibb big-pharma
Oncology, Gastroenterology, Infectious Disease
Active (1)
Discontinued (7)
Company Info
- First Approval
- 1993-09-09
- Latest
- 2025-06-06
- Applications
- 8
FDA Sponsor Names
SHIONOGI INCSHIONOGI